How to select cancer patients for immunotherapy

by Per Pfeiffer, Camilla Qvortrup, Karin Holmskov Hansen
Published 2021-01-01

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data

by Torben Frøstrup Hansen, Camilla Qvortrup, Per Pfeiffer
Published 2021-03-01

Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?

by Per Pfeiffer, Thomas Gruenberger, Robert Glynne-Jones
Published 2018-08-01

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients

by Per Pfeiffer, Camilla Qvortrup, Jon K Bjerregaard
Published 2008-12-01

Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review

by Magnus Ploug, Martin Graversen, Per Pfeiffer, Michael Bau Mortensen
Published 2020-02-01

Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis

by Martin Graversen, Sönke Detlefsen, Jon Kroll Bjerregaard, Claus Wilki Fristrup, Per Pfeiffer, Michael Bau Mortensen
Published 2018-06-01

Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin

by Madoka Takeuchi, Jaffer A. Ajani, Xuemin Fang, Per Pfeiffer, Masahiro Takeuchi, Hanneke W. M. van Laarhoven
Published 2019-06-01

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

by Christina Siesing, Halfdan Sorbye, Anca Dragomir, Per Pfeiffer, Camilla Qvortrup, Fredrik Pontén, Karin Jirström, Bengt Glimelius, Jakob Eberhard
Published 2017-01-01

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy f...

by Stine Braendegaard Winther, Pia Österlund, Åke Berglund, Bengt Glimelius, Camilla Qvortrup, Halfdan Sorbye, Per Pfeiffer, - on behalf of the Academy of Geriatric Cancer Research (AgeCare)
Published 2017-08-01

Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer

by Karen-Lise Garm Spindler, Christina Demuth, Boe Sandahl Sorensen, Julia S Johansen, Dorte Nielsen, Niels Pallisgaard, Estrid Hoegdall, Per Pfeiffer, Benny Vittrup Jensen
Published 2018-11-01

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients

by Kristine Ø. Aasebø, Anca Dragomir, Magnus Sundström, Artur Mezheyeuski, Per‐Henrik Edqvist, Geir Egil Eide, Fredrik Ponten, Per Pfeiffer, Bengt Glimelius, Halfdan Sorbye
Published 2019-07-01

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Met...

by Halfdan Sorbye, Anca Dragomir, Magnus Sundström, Per Pfeiffer, Ulf Thunberg, Monica Bergfors, Kristine Aasebø, Geir Egil Eide, Fredrik Ponten, Camilla Qvortrup, Bengt Glimelius
Published 2015-01-01

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

by Jakob V Schou, Simona Rossi, Benny V Jensen, Dorte L Nielsen, Per Pfeiffer, Estrid Høgdall, Mette Yilmaz, Sabine Tejpar, Mauro Delorenzi, Mogens Kruhøffer, Julia S Johansen
Published 2014-01-01

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

by Line S Tarpgaard, Tormod K Guren, Bengt Glimelius, Ib J Christensen, Per Pfeiffer, Elin H Kure, Halfdan Sorbye, Tone Ikdahl, Mette Yilmaz, Julia S Johansen, Kjell Magne Tveit
Published 2014-01-01

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

by Kristine Aasebø, Anca Dragomir, Anca Dragomir, Magnus Sundström, Magnus Sundström, Artur Mezheyeuski, Per-Henrik Edqvist, Geir Egil Eide, Geir Egil Eide, Fredrik Ponten, Fredrik Ponten, Per Pfeiffer, Bengt Glimelius, Halfdan Sorbye, Halfdan Sorbye
Published 2020-02-01

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study

by Gabor Liposits, Henrik Rode Eshøj, Sören Möller, Stine Brændegaard Winther, Halla Skuladottir, Jesper Ryg, Eva Hofsli, Carl-Henrik Shah, Laurids Østergaard Poulsen, Åke Berglund, Camilla Qvortrup, Pia Österlund, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer
Published 2021-05-01

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells

by Mads Heilskov Rasmussen, Iben Lyskjær, Rosa Rakownikow Jersie-Christensen, Line Schmidt Tarpgaard, Bjarke Primdal-Bengtson, Morten Muhlig Nielsen, Jakob Skou Pedersen, Tine Plato Hansen, Flemming Hansen, Jesper Velgaard Olsen, Per Pfeiffer, Torben Falck Ørntoft, Claus Lindbjerg Andersen
Published 2016-08-01

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer

by Jesper Andreas Palshof, Camilla Natasha Cederbye, Estrid Vilma Solyom Høgdall, Tim Svenstrup Poulsen, Dorte Linnemann, Sune Boris Nygaard, Jan Stenvang, Ib Jarle Christensen, Benny Vittrup Jensen, Per Pfeiffer, Nils Brünner, Mette Yilmaz, Birgitte Martine Viuff, Dorte Lisbet Nielsen
Published 2020-07-01

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

by Mogens K Boisen, Christian Dehlendorff, Dorte Linnemann, Boye S Nielsen, Jim S Larsen, Kell Osterlind, Svend E Nielsen, Line S Tarpgaard, Camilla Qvortrup, Per Pfeiffer, Niels H Holländer, Nina Keldsen, Torben F Hansen, Brita B Jensen, Estrid V S Høgdall, Benny V Jensen, Julia S Johansen
Published 2014-01-01

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

by Nicolai A Schultz, Ib J Christensen, Jens Werner, Nathalia Giese, Benny V Jensen, Ole Larsen, Jon K Bjerregaard, Per Pfeiffer, Dan Calatayud, Svend E Nielsen, Mette K Yilmaz, Niels H Holländer, Morten Wøjdemann, Stig E Bojesen, Kaspar R Nielsen, Julia S Johansen
Published 2013-01-01